Last reviewed · How we verify

DTG/3TC/ABC + ELV/COBI/FTC/TAF

Fundacion SEIMC-GESIDA · FDA-approved active Small molecule

This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication.

This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve or treatment-experienced adults.

At a glance

Generic nameDTG/3TC/ABC + ELV/COBI/FTC/TAF
SponsorFundacion SEIMC-GESIDA
Drug classAntiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)
TargetHIV integrase, HIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

DTG/3TC/ABC (dolutegravir/lamivudine/abacavir) combines an integrase strand transfer inhibitor with two nucleoside reverse transcriptase inhibitors. ELV/COBI/FTC/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) combines another integrase inhibitor with a pharmacokinetic booster and two nucleotide/nucleoside reverse transcriptase inhibitors. Together, these agents target multiple steps of HIV replication to achieve viral suppression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: